AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer from dll videos Watch Video
Preview(s): Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Your browser does not support playing the video.Please download the video!
Description: Dr Luis Paz-Ares speaks to ecancer about the phase 1 study of AMG 75; a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC). Initially, he explains the rationale of this study. Then Dr Paz-Ares discusses the methods and results of this study. He says that AMG 757 showed an acceptable safety profile and preliminary evidence for efficacy in patients with SCLC. The maximum tolerated dose has not been reached. D